FDA has expanded the approval of Zelboraf (vemurafenib), a kinase inhibitor, to include the treatment of certain adult patients with Erdheim-Chester Disease, a rare blood cancer. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
